CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Total Non-Current Liabilities data on file, last reported at $905.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 171.36% year-over-year to $905.3 million; the trailing twelve-month figure through Mar 2026 stood at $905.3 million (up 171.36% YoY), and the FY2025 full-year result was $337.3 million, up 10.04% from the prior year.
• Total Non-Current Liabilities climbed to $905.3 million in Q1 2026, from $337.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $905.3 million in Q1 2026 to a low of $306.5 million in Q4 2024.
• A 5-year average of $380.9 million and a median of $353.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities declined 11.58% in 2025 and surged 171.36% in 2026, its largest moves.
• Tracing CRSP's Total Non-Current Liabilities over 5 years: stood at $361.6 million in 2022, then dropped by 4.37% to $345.8 million in 2023, then declined by 11.36% to $306.5 million in 2024, then advanced by 10.04% to $337.3 million in 2025, then jumped by 168.41% to $905.3 million in 2026.
• Business Quant data shows CRSP's Total Non-Current Liabilities at $905.3 million in Q1 2026, $337.3 million in Q4 2025, and $324.0 million in Q3 2025.